CNS Pharmaceuticals, Inc. (CNSP)
| Market Cap | 45.80M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.98M |
| Shares Out | 16.48M |
| EPS (ttm) | -0.64 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 19 |
| Last Price | $2.02 |
| Previous Close | $1.92 |
| Change ($) | 0.10 |
| Change (%) | 5.21% |
| Day's Open | 1.96 |
| Day's Range | 1.91 - 2.04 |
| Day's Volume | 2,776,773 |
| 52-Week Range | 1.45 - 4.60 |
Looking for penny stocks to buy? Click for seven that are hot right now and should continue to rise in the future.
CNS Pharmaceuticals Featured in Syndicated Broadcast Covering Recent FDA Approval of IND Application
HOUSTON, Dec. 28, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – CNS Pharmaceuticals, Inc . (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for pri...
HOUSTON, Dec. 18, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for pr...
HOUSTON, Dec. 17, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for pr...
HOUSTON, Nov. 24, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for prim...
HOUSTON, Oct. 9, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for pri...
HOUSTON, Sept. 24, 2020 (GLOBE NEWSWIRE) -- via NetworkWire -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development ...
HOUSTON, Sept. 11, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc.
Houston, Texas, Sept. 03, 2020 (GLOBE NEWSWIRE) -- via NetworkWire – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the develo...
HOUSTON, Aug. 27, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc.
HOUSTON, Aug. 20, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc.
HOUSTON, July 22, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for pr...
HOUSTON, July 8, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for pri...
HOUSTON, May 28, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for pri...
HOUSTON, May 27, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc., (Nasdaq: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for pr...
HOUSTON, May 27, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc., (Nasdaq: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for pr...
Moleculin Biotech Inc. MBRX, -1.83% and CNS Pharmaceuticals Inc. CNSP, -3.83% said Monday their shares remain halted on Nasdaq with the exchange seeking additional information from each company.
HOUSTON, May 18, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc., (Nasdaq: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for pr...
Moleculin Biotech Inc. MBRX, -1.83% and CNS Pharmaceuticals Inc. CNSP, -3.83% said Monday they did not solicit or have any advance knowledge about claims made by third parties about drug candi...
CNS Pharmaceuticals (NASDAQ: CNSP) shares are trading higher on Monday. The company announced that independent research from the University of Frankfurt showed that an active compound in WP112...
Nano-cap biotech CNS Pharmaceuticals Inc (NASDAQ: CNSP), which develops treatments for cancers of the brain and central nervous systems, said Monday that it has struck an agreement with Canada...
CNS Pharmaceuticals, Inc. (CNSP) Management on Q4 2019 Results - Earnings Call Transcript
About CNSP
CNS Pharmaceuticals, a biopharmaceutical company, engages in the development of anti-cancer drug candidates for primary and metastatic cancers of the brain and central nervous system. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. CNS Pharmaceuticals, Inc. was founded in 201... [Read more...]
| Industry Biotechnology | IPO Date Nov 8, 2019 |
| CEO John Michael Climaco Esq., J.D. | Employees 3 |
| Stock Exchange NASDAQ | Ticker Symbol CNSP |
Analyst Forecasts
According to 3 analysts, the average rating for CNSP stock is "Buy." The 12-month stock price forecast is 7.50, which is an increase of 271.29% from the latest price.